Tesamorelin vs sermorelin peptide: how they actually differ

Last updated 2026-07-24

What is the real difference between tesamorelin and sermorelin?

Both are synthetic growth-hormone-releasing hormone (GHRH) analogs. That means both work the same way: they bind to GHRH receptors on the pituitary gland and stimulate it to make and release the body's own growth hormone, rather than replacing growth hormone directly the way injectable HGH (somatropin) does. The practical difference is regulatory status and structure. Tesamorelin is a modified 44-amino-acid peptide with a trans-3-hexenoic acid group added to the front end, which slows its breakdown and gives it a longer effective action. It's sold under the brand name Egrifta (and Egrifta SV, a reformulated version) and is FDA-approved for a single, specific indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ^[1]. Sermorelin is a shorter peptide, the first 29 amino acids of native human GHRH (GHRH 1-29), which is the smallest fragment that retains full biological activity. It was FDA-approved in the 1990s under the brand name Geref for diagnosing and treating growth hormone deficiency, primarily in children. The manufacturer discontinued Geref in 2008 for commercial reasons, not because of a safety recall ^[2]. No sermorelin product currently holds FDA approval; what's available today comes from compounding pharmacies, prepared under a licensed prescriber's order for an individual patient, per the compounding framework in Section 503A of the Food, Drug, and Cosmetic Act ^[3]. So the honest framing: tesamorelin is an approved drug with a specific, proven use. Sermorelin is a peptide with real regulatory history but no current approval, used off-label based on older data and clinical experience.

How do tesamorelin and sermorelin compare on FDA approval status?

This is the single biggest difference and it changes what a prescriber can legally claim and what a pharmacy can legally dispense. Tesamorelin (Egrifta) went through the full New Drug Application process and was approved by the FDA in November 2010 specifically for reducing visceral adipose tissue in HIV patients with lipodystrophy ^[1]. It has a full prescribing label, defined manufacturing standards, and post-market safety monitoring under normal FDA drug rules. Sermorelin's approval (as Geref, and a related product Geref Diagnostic) covered growth hormone deficiency workup and treatment, mostly in pediatric patients, and mostly for diagnostic stimulation testing. That approval lapsed when the manufacturer stopped making the branded product in 2008. The FDA didn't pull it for safety reasons; the company simply stopped selling it, which happens routinely with older, low-revenue drugs ^[2]. Today, if you get sermorelin, it's compounded. Compounded drugs aren't FDA-approved products; they're prepared to order under state pharmacy board oversight and 503A rules, which means no FDA review of that specific batch's safety or effectiveness ^[3]. That's not automatically dangerous, but it's a different regulatory tier than an approved drug like tesamorelin, and readers deciding between the two should know which category they're actually choosing.

What is each peptide actually FDA-approved (or used off-label) for?

Tesamorelin has one narrow, approved lane: reducing excess visceral fat in HIV-associated lipodystrophy, studied in randomized, placebo-controlled trials showing measurable reductions in visceral adipose tissue over 26 to 52 weeks ^[1][4]. It is not approved for bodybuilding, general fat loss, or anti-aging use, even though it gets marketed that way in some gray-market settings. Sermorelin's old approval was for growth hormone deficiency diagnosis and pediatric treatment. Its current off-label use is broader and murkier: adults seeking higher GH/IGF-1 levels for reasons like low energy, poor sleep, or general "optimization." There isn't strong modern trial evidence supporting sermorelin for those adult wellness goals; most of the data behind it is decades old and focused on confirmed GH deficiency, not healthy adults chasing higher IGF-1. Read the sermorelin overview for the full evidence picture before assuming it does anything beyond what's been studied.

How does dosing compare between tesamorelin and sermorelin?

Tesamorelin's approved dose is straightforward because it comes from a package insert: 2 mg injected subcutaneously once daily, reconstituted from the single-dose vial ^[1]. There's no titration ritual, no dose range to figure out with a prescriber; it's one dose, one schedule, because that's what got studied and approved. Sermorelin dosing is far less standardized because it isn't an approved product with a label to consult. Compounding pharmacies and prescribers typically use doses in the range of 200 to 300 mcg per day, injected subcutaneously at night to mimic the body's natural GH pulse, though protocols vary by pharmacy and provider. If a prescriber puts you on sermorelin, expect a plan built around your weight, goals, and response rather than a single fixed number. For actual numbers and how they get chosen, see the sermorelin dosage chart and, if you want to model your own dose against a compounded vial's concentration, the sermorelin dosage calculator.

Which one costs more, tesamorelin or sermorelin?

Tesamorelin as a branded, FDA-approved product is expensive. Egrifta and Egrifta SV commonly run well over $1,000 to $2,000 per month without insurance coverage, reflecting typical specialty biologic drug pricing, though exact retail cost varies by pharmacy and any manufacturer assistance program. Because its approved indication is narrow (HIV lipodystrophy), insurance coverage outside that diagnosis is unlikely, and off-label prescribing for other goals means paying cash at that price point. Compounded sermorelin is generally cheaper, often landing somewhere in the low-to-mid hundreds of dollars per month depending on the pharmacy, dose, and region, though prices aren't standardized the way an FDA-approved drug's list price roughly is. There's no insurance angle here either, since it's an off-label compounded product, but the price floor tends to be lower than tesamorelin simply because the peptide itself and the compounding process cost less than a full approved biologic manufacturing pipeline. Neither price is something we'll pin to an exact number here, because compounding pharmacy pricing shifts by supplier and region and isn't published the way a drug label is. Get a quote from the actual pharmacy your prescriber uses before assuming either figure.

Is tesamorelin more effective than sermorelin, or just more studied?

For its approved indication, tesamorelin has the stronger trial base by a wide margin. The key studies enrolled hundreds of HIV patients with lipodystrophy and showed statistically significant reductions in visceral adipose tissue compared to placebo over 26-52 weeks, which is exactly the kind of randomized, controlled evidence the FDA required for approval ^[1][4]. Sermorelin's evidence base is older and narrower. Most of the controlled data comes from studies of children and adults with diagnosed GH deficiency, run before and around its Geref approval in the 1990s, showing it can stimulate GH release and support growth in deficient patients. There isn't a comparable modern trial showing sermorelin produces meaningful body composition or anti-aging benefits in healthy adults with normal GH levels. If your actual goal is "more studied, FDA-backed evidence for a specific condition," tesamorelin wins that comparison, but only within its one approved lane. Outside HIV lipodystrophy, neither peptide has strong modern trial support for general wellness claims, and claims of anti-aging or performance benefit from either one outrun the evidence.

How does sermorelin compare to HGH itself, more than to tesamorelin?

This is probably the question underneath the tesamorelin question for a lot of readers, so it's worth answering directly. Sermorelin doesn't replace growth hormone; it stimulates your own pituitary to make more of it. HGH (somatropin) is the hormone itself, injected directly. That difference matters in both directions. Because sermorelin works through your pituitary, it generally can't push GH levels arbitrarily high; the pituitary has some built-in negative feedback, which may make severe overdose less likely than with direct HGH injection. But it also means sermorelin won't work at all in someone whose pituitary is severely damaged or nonfunctional, since there's nothing left to stimulate. Direct HGH bypasses that limitation entirely. HGH also has broader FDA-approved uses (childhood growth failure, adult GH deficiency, certain wasting syndromes) and a much larger body of long-term outcome data, simply because it's been an approved, tracked drug for far longer. Sermorelin's approval history is thinner and now lapsed. If your prescriber is choosing between the two for a diagnosed deficiency, HGH has the deeper evidence base; sermorelin's appeal is a milder release profile and, for some patients, a preference for working with the body's own regulatory feedback rather than overriding it. Neither choice should be framed as an anti-aging or athletic performance tool; that's not what the approved evidence supports for either compound.

What are the side effects of tesamorelin vs sermorelin?

Tesamorelin's side effect profile comes from its FDA label and trials: injection site reactions (redness, itching, pain) are the most common complaint, along with joint pain (arthralgia), swelling from fluid retention, and, because it raises IGF-1, a theoretical concern about tumor growth in patients with active malignancy, which is why the label carries a warning against use in patients with active cancer ^[1]. Blood glucose can also rise, so it's used cautiously in anyone with diabetes risk. Sermorelin's reported side effects, drawn from its older approval data and post-market use, are similar in category: injection site redness or irritation, flushing, headache, and occasionally dizziness. Because it stimulates rather than replaces GH, and works through the pituitary's feedback loop, some clinicians consider its overdose and side-effect risk profile milder than direct HGH, though this hasn't been tested head-to-head in rigorous modern trials. For a fuller rundown of what to watch for over months of use, see sermorelin long-term side effects. Neither peptide is risk-free, and neither has a long enough modern safety record in healthy adults using it off-label to make confident long-term statements. That's a real gap in the evidence, not a minor caveat.

Can you switch between tesamorelin and sermorelin, or use them together?

Prescribers don't typically combine two GHRH analogs; there's no established protocol or trial data supporting stacking tesamorelin and sermorelin together, and doing so would mean paying for two products that work through the identical mechanism without a clear rationale for added benefit. Switching is a more realistic scenario. Someone prescribed tesamorelin for an approved indication (HIV lipodystrophy) who can't tolerate the cost or side effects might discuss alternatives with their prescriber, though sermorelin isn't a direct substitute since it doesn't carry the same approval or trial support for that specific condition. Someone using compounded sermorelin off-label who wants a longer-acting option might ask about tesamorelin, but should go in clear-eyed that tesamorelin's approval doesn't cover their use case either, unless they actually have HIV-associated lipodystrophy. The decision should sit with a prescriber who knows your labs, your goals, and your risk factors, not with a peptide vendor's marketing copy.

Where can you legally get tesamorelin or sermorelin?

Tesamorelin (Egrifta, Egrifta SV) is dispensed through normal pharmacy channels as an FDA-approved specialty drug, requiring a prescription and typically routed through specialty pharmacies familiar with HIV-related medications. Sermorelin, since there's no current FDA-approved product, comes only through compounding pharmacies operating under Section 503A, which requires a valid prescription written for an individual patient by a licensed prescriber ^[3]. That means no legitimate route to sermorelin skips the prescriber step. Buying "research peptide" sermorelin online without a prescription puts you outside any pharmacy oversight, with no guarantee of purity, sterility, or accurate dosing, since those products aren't inspected the way a licensed pharmacy's compounded order is. If you're trying to figure out what a legitimate path actually looks like near you, sermorelin peptide near me walks through how to find a provider and pharmacy that do this correctly, and sermorelin reviews covers what real patient experiences (and complaints) tend to look like. Sermorelin Co connects readers with provider-reviewed evaluations and routes prescriptions to a licensed compounding pharmacy partner for fulfillment; it doesn't compound or manufacture anything itself, and a legitimate prescriber conversation should always come before any purchase decision.

Which one should you actually ask your prescriber about?

If you have HIV-associated lipodystrophy with excess visceral fat, tesamorelin is the one with FDA approval and trial data built specifically for that problem, and it's worth a direct conversation with an HIV specialist or endocrinologist about whether you're a candidate ^[1][4]. If you're an adult with confirmed or suspected growth hormone deficiency, or you're curious about a milder, pituitary-stimulating approach rather than direct HGH replacement, sermorelin is the more commonly discussed off-label option, but go in knowing it's compounded, not FDA-approved, and the modern evidence in healthy adults is thin. Ask for baseline labs (IGF-1 at minimum) before starting, and get a real dosing plan rather than a generic protocol. If your actual goal is general anti-aging, muscle gain, or performance enhancement with no diagnosed deficiency, neither peptide has approved evidence supporting that use, and you should hear that plainly from anyone prescribing it, not from a marketing page.

Frequently asked questions

Is tesamorelin stronger than sermorelin?

They're not directly comparable as "stronger." Tesamorelin is a modified, longer-acting GHRH analog with FDA approval for one specific condition (HIV lipodystrophy) and stronger trial data for that use. Sermorelin is a shorter native GHRH fragment with older, narrower approval history now lapsed. Neither has been tested head-to-head for general GH-boosting strength in healthy adults.

Why was sermorelin discontinued?

The branded product Geref was discontinued by its manufacturer in 2008 for business reasons, not pulled by the FDA for a safety problem. It's a common outcome for older, lower-revenue drugs once patents age and profitability drops. Sermorelin itself remains legally available today only through compounding pharmacies under a prescriber's order.

Is tesamorelin FDA-approved and is sermorelin FDA-approved?

Tesamorelin (Egrifta, Egrifta SV) is FDA-approved, specifically for reducing excess abdominal fat in HIV patients with lipodystrophy. Sermorelin was FDA-approved as Geref in the 1990s but that approval lapsed when the product was discontinued in 2008. No sermorelin product holds current FDA approval; it's available only as a compounded preparation.

Does tesamorelin or sermorelin work better for fat loss?

Tesamorelin has real trial evidence for reducing visceral abdominal fat, but only in HIV patients with lipodystrophy, which is its approved indication. Sermorelin doesn't have comparable modern trial evidence for fat loss in any population. Neither should be assumed to produce general fat loss in someone without a diagnosed deficiency or lipodystrophy condition.

How much does tesamorelin cost compared to sermorelin?

Tesamorelin as a branded specialty drug often costs well over $1,000 a month without insurance, and insurance rarely covers it outside the approved HIV lipodystrophy indication. Compounded sermorelin is usually cheaper, often in the low-to-mid hundreds monthly, though pricing varies by pharmacy and isn't standardized like an FDA-approved drug's list price.

Can sermorelin be used instead of HGH?

Sometimes, if the pituitary still functions. Sermorelin stimulates your own GH release rather than replacing it, so it can't work in someone whose pituitary can't respond. HGH bypasses that entirely by supplying the hormone directly. A prescriber choosing between them looks at pituitary function, diagnosis, and goals, not a generic preference for one over the other.

Is sermorelin safer than tesamorelin?

There's no rigorous head-to-head safety trial comparing them. Both share GHRH-analog side effects like injection site reactions and joint or fluid-related complaints. Tesamorelin's label carries specific warnings around active malignancy given IGF-1 elevation. Sermorelin's stimulatory mechanism may carry a milder overdose profile in theory, but that hasn't been tested rigorously in modern trials.

Can you buy tesamorelin or sermorelin without a prescription?

Not legally through a legitimate channel. Tesamorelin is a prescription-only approved drug. Sermorelin, being compounded, legally requires a prescription written for an individual patient under 503A rules. Products sold online as "research chemicals" without a prescription skip all pharmacy oversight and carry real purity and dosing risk.

What is tesamorelin actually approved to treat?

Tesamorelin is FDA-approved specifically to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy, based on randomized placebo-controlled trials showing measurable fat reduction over roughly six months to a year of use. It is not approved for anti-aging, bodybuilding, or general weight loss in people without HIV-associated lipodystrophy.

How is sermorelin dosed compared to tesamorelin?

Tesamorelin's approved dose is a fixed 2 mg subcutaneous injection once daily, per its FDA label. Sermorelin has no FDA label to reference; compounding pharmacies and prescribers commonly use roughly 200 to 300 mcg per day at bedtime, adjusted by weight and response, since dosing isn't standardized the way an approved drug's is.

Does insurance cover tesamorelin or sermorelin?

Insurance may cover tesamorelin only when prescribed for its approved indication, HIV-associated lipodystrophy, and even then coverage varies by plan. Off-label use of either drug is almost never covered. Sermorelin, being a compounded off-label product, is essentially never covered by insurance, so expect to pay out of pocket either way.

Which peptide has more long-term human data, tesamorelin or sermorelin?

Tesamorelin has more recent, rigorous long-term data because it went through FDA trials for approval in 2010 and has ongoing post-market monitoring. Sermorelin's strongest data is older, from its 1990s approval era, mostly in GH-deficient patients rather than healthy adults using it off-label today, which leaves a real gap in modern long-term evidence.

Sources

1. FDA prescribing information, Egrifta (tesamorelin for injection), NDA 022505: Tesamorelin is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, dosed at 2 mg subcutaneous daily, with label warnings on malignancy and glucose effects
2. FDA, Determination That GEREF (Sermorelin Acetate) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, Federal Register: Geref (branded sermorelin) was discontinued by its manufacturer for commercial reasons, and FDA determined it was not withdrawn for safety or effectiveness reasons
3. 21 U.S.C. 353a, Pharmacy compounding (Section 503A of the Federal Food, Drug, and Cosmetic Act): Compounded drugs like sermorelin are prepared under 503A requirements based on a valid patient-specific prescription, without individual FDA product approval
4. Falutz J, et al. "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension." J Acquir Immune Defic Syndr, 2010, PMID 19910308: Randomized placebo-controlled trials of HIV lipodystrophy patients showed significant visceral adipose tissue reduction with tesamorelin over 26-52 weeks
5. Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." N Engl J Med, 2007, PMID 17671248: An earlier randomized controlled trial established tesamorelin's effect on reducing visceral adipose tissue in HIV-associated lipodystrophy, forming part of the basis for its approval
6. MedlinePlus (National Library of Medicine), Tesamorelin Injection: Tesamorelin injection is described as indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, with common side effects including injection site reactions and joint pain
7. MedlinePlus (National Library of Medicine), Growth Hormone Deficiency: Growth hormone deficiency and its diagnosis and treatment context, relevant to sermorelin's original approved use in GH deficiency
8. U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers: FDA guidance describing how compounded medications differ from FDA-approved drugs in terms of review and oversight